Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD)

Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma. […]

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Read More Ā»